MX2023009151A - Composiciones para el tratamiento de afecciones y enfermedades asociadas con la expresion de policistina. - Google Patents
Composiciones para el tratamiento de afecciones y enfermedades asociadas con la expresion de policistina.Info
- Publication number
- MX2023009151A MX2023009151A MX2023009151A MX2023009151A MX2023009151A MX 2023009151 A MX2023009151 A MX 2023009151A MX 2023009151 A MX2023009151 A MX 2023009151A MX 2023009151 A MX2023009151 A MX 2023009151A MX 2023009151 A MX2023009151 A MX 2023009151A
- Authority
- MX
- Mexico
- Prior art keywords
- expression
- polycystin
- compositions
- treatment
- conditions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/313—Phosphorodithioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163145288P | 2021-02-03 | 2021-02-03 | |
| PCT/US2022/015074 WO2022169947A2 (en) | 2021-02-03 | 2022-02-03 | Compositions for treatment of conditions and diseases associated with polycystin expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023009151A true MX2023009151A (es) | 2023-10-19 |
Family
ID=82741748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023009151A MX2023009151A (es) | 2021-02-03 | 2022-02-03 | Composiciones para el tratamiento de afecciones y enfermedades asociadas con la expresion de policistina. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240117353A1 (https=) |
| EP (1) | EP4288543A4 (https=) |
| JP (1) | JP2024507717A (https=) |
| KR (1) | KR20230150973A (https=) |
| CN (1) | CN117413061A (https=) |
| AR (1) | AR124809A1 (https=) |
| AU (1) | AU2022215577A1 (https=) |
| BR (1) | BR112023015636A2 (https=) |
| CA (1) | CA3207341A1 (https=) |
| MX (1) | MX2023009151A (https=) |
| TW (1) | TW202242113A (https=) |
| WO (1) | WO2022169947A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4612295A1 (en) * | 2022-10-31 | 2025-09-10 | Stoke Therapeutics, Inc. | Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseases |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6916619B2 (en) * | 2001-10-12 | 2005-07-12 | Athena Diagnostics, Inc. | Compositions and methods for genetic analysis of polycystic kidney disease |
| US11096956B2 (en) * | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
| JP2018538287A (ja) * | 2015-12-14 | 2018-12-27 | コールド スプリング ハーバー ラボラトリー | 多発性嚢胞腎の処置のためのアンチセンスオリゴマー |
| HUE070436T2 (hu) * | 2017-10-23 | 2025-06-28 | Stoke Therapeutics Inc | Antiszensz oligomerek nonszensz-mediált RNS-lebomláson alapuló állapotok és betegségek kezelésére |
-
2022
- 2022-02-03 CN CN202280019548.3A patent/CN117413061A/zh active Pending
- 2022-02-03 AU AU2022215577A patent/AU2022215577A1/en active Pending
- 2022-02-03 BR BR112023015636A patent/BR112023015636A2/pt unknown
- 2022-02-03 WO PCT/US2022/015074 patent/WO2022169947A2/en not_active Ceased
- 2022-02-03 KR KR1020237029596A patent/KR20230150973A/ko active Pending
- 2022-02-03 JP JP2023547237A patent/JP2024507717A/ja active Pending
- 2022-02-03 CA CA3207341A patent/CA3207341A1/en active Pending
- 2022-02-03 MX MX2023009151A patent/MX2023009151A/es unknown
- 2022-02-03 AR ARP220100222A patent/AR124809A1/es unknown
- 2022-02-03 EP EP22750375.2A patent/EP4288543A4/en active Pending
- 2022-02-07 TW TW111104414A patent/TW202242113A/zh unknown
-
2023
- 2023-08-02 US US18/364,244 patent/US20240117353A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023015636A2 (pt) | 2024-01-02 |
| WO2022169947A2 (en) | 2022-08-11 |
| JP2024507717A (ja) | 2024-02-21 |
| AU2022215577A1 (en) | 2023-09-21 |
| CA3207341A1 (en) | 2022-08-11 |
| KR20230150973A (ko) | 2023-10-31 |
| CN117413061A (zh) | 2024-01-16 |
| TW202242113A (zh) | 2022-11-01 |
| EP4288543A2 (en) | 2023-12-13 |
| AR124809A1 (es) | 2023-05-10 |
| EP4288543A4 (en) | 2025-11-26 |
| US20240117353A1 (en) | 2024-04-11 |
| WO2022169947A3 (en) | 2022-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4494706A3 (en) | Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseases | |
| MX2022014151A (es) | Oligomeros antisentido de opa1 para tratamiento de afecciones y enfermedades. | |
| EP4303321A3 (en) | Antisense oligomers for treatment of conditions and diseases | |
| MX2022002198A (es) | Composiciones y métodos para modular el empalme y la expresión de proteínas. | |
| MX2022006858A (es) | Oligomeros antisentido para el tratamiento de condiciones y enfermedades. | |
| MX2021012989A (es) | Metodos y composiciones para modular el empalme y la traduccion. | |
| Zhang et al. | Cerebral mast cells contribute to postoperative cognitive dysfunction by promoting blood brain barrier disruption | |
| EP4491229A3 (en) | Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases | |
| EA202091144A1 (ru) | Ганаксолон для использования в лечении наследственных эпилептических заболеваний | |
| EA201490994A1 (ru) | Функционально-модифицированные олигонуклеотиды и их субъединицы | |
| WO2023086342A3 (en) | Opa1 antisense oligomers for treatment of conditions and diseases | |
| MX2009009146A (es) | Metodos y objetivos para identificar compuestos para regular la infeccion por rinovirus. | |
| CY1111478T1 (el) | Ενδειξη δοσολογιας προγεστερονης στην αντιμετωπιση τραυματικης εγκεφαλικης βλαβης | |
| TW201712023A (en) | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | |
| IL192557A (en) | Imidazole derivatives are conserved and used as ptpase inhibitors | |
| MX2024000237A (es) | Arnip que inhibe la expresión del gen angptl3 y uso del mismo. | |
| Wu et al. | High glucose promotes IL-17A-induced gene expression through histone acetylation in retinal pigment epithelium cells | |
| WO2024026122A3 (en) | Compounds for treatment of conditions and diseases | |
| WO2019010301A8 (en) | Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap) | |
| WO2022271699A3 (en) | Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseases | |
| MX2023009151A (es) | Composiciones para el tratamiento de afecciones y enfermedades asociadas con la expresion de policistina. | |
| MY203356A (en) | Antisense oligonucleotides targeting alpha-synuclein and uses thereof | |
| WO2024249949A3 (en) | Opa1 antisense oligomers for treatment of conditions and diseases | |
| MY190709A (en) | A polypeptide from mormodica charantia for use for the regulation of genes related to inflammation, lipid and glucose metabolism | |
| EA202290027A1 (ru) | Способы и композиции для улучшения результатов лечения пациентов с раком |